Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis.

Leung YY, Orbai AM, Ogdie A, Hojgaard P, Holland R, Goel N, Chau J, Coates LC, Strand V, Gladman DD, Mease P, Christensen R, Tillett W.

J Rheumatol. 2020 Feb 1. pii: jrheum.191119. doi: 10.3899/jrheum.191119. [Epub ahead of print]

PMID:
32007934
2.

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).

Orbai AM, Ogdie A, Gossec L, Tillett W, Leung YY, Gao J, Trivedi M, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Coates LC.

Rheumatology (Oxford). 2019 Oct 18. pii: kez408. doi: 10.1093/rheumatology/kez408. [Epub ahead of print]

PMID:
31624837
3.

Diagnosis and initial management in psoriatic arthritis: a qualitative study with patients.

Dures E, Bowen C, Brooke M, Lord J, Tillett W, McHugh N, Hewlett S.

Rheumatol Adv Pract. 2019 Aug 26;3(2):rkz022. doi: 10.1093/rap/rkz022. eCollection 2019.

4.

Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs.

McHugh N, Maguire Á, Handel I, Tillett W, Morris J, Hawkins N, Cavill C, Korendowych E, Mughal F.

J Rheumatol. 2019 Aug 15. pii: jrheum.190083. doi: 10.3899/jrheum.190083. [Epub ahead of print]

PMID:
31416922
5.

Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis.

Green A, Shaddick G, Charlton R, Snowball J, Nightingale A, Smith C, Tillett W, McHugh N; PROMPT study group.

Br J Dermatol. 2019 Jun 18. doi: 10.1111/bjd.18227. [Epub ahead of print]

PMID:
31209855
6.

A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire.

Tillett W, Lin CY, Zbrozek A, Sprabery AT, Birt J.

Rheumatol Ther. 2019 Sep;6(3):379-391. doi: 10.1007/s40744-019-0155-5. Epub 2019 Jun 1.

7.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W.

J Rheumatol Suppl. 2019 Jun;95:33-37. doi: 10.3899/jrheum.190122.

PMID:
31154402
8.

Correction to: Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study.

Dures E, Hewlett S, Lord J, Bowen C, McHugh N; PROMPT Study Group, Tillett W.

Patient. 2019 Aug;12(4):437. doi: 10.1007/s40271-019-00362-1.

9.

Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study.

Antony AS, Allard A, Rambojun A, Lovell CR, Shaddick G, Robinson G, Jadon DR, Holland R, Cavill C, Korendowych E, McHugh NJ, Tillett W.

J Rheumatol. 2019 Sep;46(9):1097-1102. doi: 10.3899/jrheum.180796. Epub 2019 Mar 1.

PMID:
30824637
10.

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Aug;46(8):996-1005. doi: 10.3899/jrheum.181089. Epub 2019 Feb 15.

PMID:
30770518
11.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Duffin KC, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2019 Aug;46(8):990-995. doi: 10.3899/jrheum.181077. Epub 2018 Dec 15.

PMID:
30554154
12.

Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis.

Allard A, Antony A, Shaddick G, Jadon DR, Cavill C, Robinson G, Korendowych E, McHugh N, Tillett W.

Rheumatology (Oxford). 2019 Feb 1;58(2):269-273. doi: 10.1093/rheumatology/key297.

PMID:
30247726
13.

Classification and Outcome Measures for Psoriatic Arthritis.

Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD.

Front Med (Lausanne). 2018 Sep 6;5:246. doi: 10.3389/fmed.2018.00246. eCollection 2018. Review.

14.

Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study.

Charlton R, Green A, Shaddick G, Snowball J, Nightingale A, Tillett W, Smith C, McHugh N; PROMPT study group.

Rheumatology (Oxford). 2019 Jan 1;58(1):144-148. doi: 10.1093/rheumatology/key286.

PMID:
30202906
15.

Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases - Time for a New Dialogue?

Tillett W, Bojke L.

J Rheumatol. 2018 Aug;45(8):1075-1077. doi: 10.3899/jrheum.180197. Epub 2018 Aug 1. No abstract available.

PMID:
30068757
16.

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

Gladman DD, Coates LC, Jadon DR, Tillett W, Mease PJ, Vis M.

J Rheumatol Suppl. 2018 Jun;94:26-29. doi: 10.3899/jrheum.180132.

PMID:
29858349
17.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
18.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

19.

Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice.

Holland R, Tillett W, Korendowych E, Cavill C, Waldron N, Brooke M, McHugh NJ.

Ann Rheum Dis. 2018 Mar;77(3):343-347. doi: 10.1136/annrheumdis-2017-211996. Epub 2017 Nov 16.

PMID:
29146740
20.

Comment on: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.

Tillett W.

Rheumatology (Oxford). 2018 Feb 1;57(2):401-402. doi: 10.1093/rheumatology/kex400. No abstract available.

PMID:
29126279
21.

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1198-1205. doi: 10.1002/acr.23460. Epub 2018 Jun 28.

22.

Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study.

Charlton R, Green A, Shaddick G, Snowball J, Nightingale A, Tillett W, Smith CH, McHugh N; PROMPT study group.

Ann Rheum Dis. 2018 Feb;77(2):277-280. doi: 10.1136/annrheumdis-2017-212328. Epub 2017 Nov 1.

PMID:
29092855
23.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2018 Apr;47(5):654-665. doi: 10.1016/j.semarthrit.2017.09.002. Epub 2017 Sep 9. Review.

24.

Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort.

Tillett W, Charlton R, Nightingale A, Snowball J, Green A, Smith C, Shaddick G, McHugh N.

Rheumatology (Oxford). 2017 Dec 1;56(12):2109-2113. doi: 10.1093/rheumatology/kex323.

PMID:
28968790
25.

A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis.

Tillett W, Dures E, Hewlett S, Helliwell PS, FitzGerald O, Brooke M, James J, Lord J, Bowen C, de Wit M, Orbai AM, McHugh N; PROMPT study group.

J Rheumatol. 2017 Oct;44(10):1445-1452. doi: 10.3899/jrheum.161459. Epub 2017 Aug 1.

PMID:
28765241
26.

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC; GRAPPA OMERACT Psoriatic Arthritis working group.

Ann Rheum Dis. 2018 May;77(5):e23. doi: 10.1136/annrheumdis-2017-212004. Epub 2017 Jul 26. No abstract available.

PMID:
28747326
27.

Dramatic effects of a new antimicrobial stewardship program in a rural community hospital.

Libertin CR, Watson SH, Tillett WL, Peterson JH.

Am J Infect Control. 2017 Sep 1;45(9):979-982. doi: 10.1016/j.ajic.2017.03.024. Epub 2017 May 16.

PMID:
28526311
28.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.

29.

Composite Measures of Impact and Activity in Psoriatic Arthritis: A Conceptual Framework.

Tillett W.

J Rheumatol. 2017 Mar;44(3):268-270. doi: 10.3899/jrheum.161544. No abstract available.

PMID:
28250162
30.

Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study.

Dures E, Hewlett S, Lord J, Bowen C, McHugh N; PROMPT Study Group, Tillett W.

Patient. 2017 Aug;10(4):455-462. doi: 10.1007/s40271-017-0221-4. Erratum in: Patient. 2019 Mar 23;:.

31.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A.

J Rheumatol. 2017 Oct;44(10):1522-1528. doi: 10.3899/jrheum.160904. Epub 2017 Feb 1. Erratum in: J Rheumatol. 2017 Apr;44(4):543.

32.

Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis.

Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, Clunie G, Helliwell PS, James J, Kay L, Korendowych E, Lane S, Packham J, Shaban R, Thomas ML, Williamson L, McHugh N.

Rheumatology (Oxford). 2017 Apr 1;56(4):603-612. doi: 10.1093/rheumatology/kew433.

PMID:
28013211
33.

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A.

Ann Rheum Dis. 2017 Apr;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242. Epub 2016 Sep 9.

34.

Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting.

de Wit M, Campbell W, Coates LC, Gladman DD, James J, Lindsay CA, MacDonald R, Moverley AR, Ogdie A, Orbai AM, O'Sullivan D, Parkinson A, Steinkoenig I, Tillett W, Goel N.

J Rheumatol. 2016 May;43(5):970-3. doi: 10.3899/jrheum.160117.

PMID:
27134272
35.

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.

Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, Gossec L, Lindsay CA, Steinkoenig I, Helliwell PS, McHugh NJ, Strand V, Ogdie A.

J Rheumatol. 2016 May;43(5):965-9. doi: 10.3899/jrheum.160116.

36.

Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study.

Tillett W, Shaddick G, Jadon D, Robinson G, Korendowych E, McHugh N.

J Rheumatol. 2016 Feb;43(2):367-70. doi: 10.3899/jrheum.150114. Epub 2016 Jan 15. Erratum in: J Rheumatol. 2017 Oct;44(10):1568.

PMID:
26773116
37.

Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.

Jadon DR, Shaddick G, Tillett W, Korendowych E, Robinson G, Waldron N, Cavill C, McHugh NJ.

J Rheumatol. 2015 Jul;42(7):1169-76. doi: 10.3899/jrheum.150083. Epub 2015 May 15.

PMID:
25979723
38.

Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.

Tillett W, Eder L, Goel N, De Wit M, Gladman DD, FitzGerald O, Campbell W, Helliwell PS, Gossec L, Orbai AM, Ogdie A, Strand V, McHugh NJ, Mease PJ.

J Rheumatol. 2015 Nov;42(11):2198-203. doi: 10.3899/jrheum.141156. Epub 2015 May 1. Review.

PMID:
25934828
39.

Patient information leaflets: a study of patient and physician satisfaction.

Becker K, Tillett W, Price E, Collins D, Williamson L.

J Clin Rheumatol. 2014 Dec;20(8):453. doi: 10.1097/RHU.0000000000000187. No abstract available.

PMID:
25417689
40.

Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study.

Tillett W, Shaddick G, Askari A, Cooper A, Creamer P, Clunie G, Helliwell PS, Kay L, Korendowych E, Lane S, Packham J, Shaban R, Williamson L, McHugh N.

Rheumatology (Oxford). 2015 Jan;54(1):157-62. doi: 10.1093/rheumatology/keu264. Epub 2014 Aug 13.

PMID:
25125591
41.

Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting.

de Wit M, Campbell W, FitzGerald O, Gladman DD, Helliwell PS, James J, Lindsay C, MacDonald R, McHugh NJ, Mease PJ, Orbai AM, Palominos P, Parkinson A, Tillett W, Goel N.

J Rheumatol. 2014 Jun;41(6):1206-11. doi: 10.3899/jrheum.140171.

PMID:
24882853
42.

Patient involvement in outcome measures for psoriatic arthritis.

Tillett W, Adebajo A, Brooke M, Campbell W, Coates LC, FitzGerald O, Gossec L, Helliwell P, Hewlett S, James J, Minnock P, Reast A, O'Sullivan D, de Wit M, McHugh N.

Curr Rheumatol Rep. 2014 May;16(5):418. doi: 10.1007/s11926-014-0418-7. Review.

PMID:
24623563
43.

Feasibility, reliability, and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthritis.

Tillett W, Jadon D, Shaddick G, Robinson G, Sengupta R, Korendowych E, de Vries CS, McHugh NJ.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):311-7. doi: 10.1002/acr.22104.

44.

The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.

Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes IB, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh NJ; BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR.

Rheumatology (Oxford). 2013 Oct;52(10):1754-7. doi: 10.1093/rheumatology/ket187. Epub 2013 Jul 25. No abstract available.

PMID:
23887065
45.

Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis.

Tillett W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, McHugh N.

Ann Rheum Dis. 2013 Aug;72(8):1358-61. doi: 10.1136/annrheumdis-2012-202608. Epub 2013 Jan 3.

PMID:
23291384
46.

Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis.

Jadon D, Tillett W, Wallis D, Cavill C, Bowes J, Waldron N, Dixon A, Sengupta R, Barton A, Korendowych E, McHugh NJ.

Rheumatology (Oxford). 2013 Feb;52(2):261-6. doi: 10.1093/rheumatology/kes254. Epub 2012 Oct 23.

PMID:
23093722
47.

Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype?

Tillett W, McHugh N.

Curr Rheumatol Rep. 2012 Aug;14(4):334-42. doi: 10.1007/s11926-012-0265-3. Review.

PMID:
22644331
48.

Joint count reliability in psoriatic arthritis observational trials--an unreported problem.

Tillett W, Shaddick G, Korendowych E, de Vries CS, McHugh N.

Rheumatology (Oxford). 2012 Jul;51(7):1333-4. doi: 10.1093/rheumatology/kes095. Epub 2012 May 4. No abstract available.

49.

The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study.

Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N.

J Rheumatol. 2012 Jan;39(1):154-6. doi: 10.3899/jrheum.110845. Epub 2011 Nov 15.

PMID:
22089469
50.

Work disability in psoriatic arthritis: a systematic review.

Tillett W, de-Vries C, McHugh NJ.

Rheumatology (Oxford). 2012 Feb;51(2):275-83. doi: 10.1093/rheumatology/ker216. Epub 2011 Jul 13. Review.

PMID:
21752872

Supplemental Content

Loading ...
Support Center